nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—autonomic nervous system—conduct disorder	0.108	0.181	CbGeAlD
Vandetanib—ORM1—saliva—conduct disorder	0.0637	0.107	CbGeAlD
Vandetanib—LTK—brain—conduct disorder	0.0206	0.0347	CbGeAlD
Vandetanib—EPHA8—brain—conduct disorder	0.0198	0.0332	CbGeAlD
Vandetanib—EPHA6—brain—conduct disorder	0.0165	0.0277	CbGeAlD
Vandetanib—PLK4—brain—conduct disorder	0.0163	0.0274	CbGeAlD
Vandetanib—TYRO3—brain—conduct disorder	0.0153	0.0257	CbGeAlD
Vandetanib—EPHA5—brain—conduct disorder	0.0153	0.0257	CbGeAlD
Vandetanib—LYN—brain—conduct disorder	0.0152	0.0256	CbGeAlD
Vandetanib—BMPR1B—brain—conduct disorder	0.015	0.0252	CbGeAlD
Vandetanib—MAP3K19—brain—conduct disorder	0.015	0.0252	CbGeAlD
Vandetanib—STK35—brain—conduct disorder	0.0127	0.0214	CbGeAlD
Vandetanib—ABL2—brain—conduct disorder	0.0124	0.0209	CbGeAlD
Vandetanib—EGFR—brain—conduct disorder	0.0121	0.0204	CbGeAlD
Vandetanib—FLT4—brain—conduct disorder	0.0118	0.0198	CbGeAlD
Vandetanib—RIPK2—brain—conduct disorder	0.0118	0.0197	CbGeAlD
Vandetanib—VEGFA—brain—conduct disorder	0.0117	0.0197	CbGeAlD
Vandetanib—FMO1—brain—conduct disorder	0.0117	0.0196	CbGeAlD
Vandetanib—IRAK4—brain—conduct disorder	0.0115	0.0193	CbGeAlD
Vandetanib—ERBB3—brain—conduct disorder	0.0113	0.0189	CbGeAlD
Vandetanib—MKNK1—brain—conduct disorder	0.0106	0.0177	CbGeAlD
Vandetanib—FGR—brain—conduct disorder	0.0104	0.0175	CbGeAlD
Vandetanib—RET—brain—conduct disorder	0.0104	0.0175	CbGeAlD
Vandetanib—AXL—brain—conduct disorder	0.0104	0.0175	CbGeAlD
Vandetanib—FMO3—brain—conduct disorder	0.0101	0.0169	CbGeAlD
Vandetanib—SLK—brain—conduct disorder	0.01	0.0168	CbGeAlD
Vandetanib—FYN—brain—conduct disorder	0.00973	0.0163	CbGeAlD
Vandetanib—MAP4K5—brain—conduct disorder	0.00951	0.016	CbGeAlD
Vandetanib—TEK—brain—conduct disorder	0.00951	0.016	CbGeAlD
Vandetanib—EPHB6—brain—conduct disorder	0.00908	0.0153	CbGeAlD
Vandetanib—YES1—brain—conduct disorder	0.00878	0.0147	CbGeAlD
Vandetanib—STK10—brain—conduct disorder	0.0087	0.0146	CbGeAlD
Vandetanib—SRC—brain—conduct disorder	0.00844	0.0142	CbGeAlD
Vandetanib—MAP2K5—brain—conduct disorder	0.00777	0.013	CbGeAlD
Vandetanib—KDR—brain—conduct disorder	0.00777	0.013	CbGeAlD
Vandetanib—PDGFRB—brain—conduct disorder	0.00672	0.0113	CbGeAlD
Vandetanib—ABL1—brain—conduct disorder	0.00599	0.0101	CbGeAlD
Vandetanib—ALB—brain—conduct disorder	0.00553	0.00929	CbGeAlD
Vandetanib—ABCC1—brain—conduct disorder	0.00456	0.00767	CbGeAlD
Vandetanib—ABCG2—brain—conduct disorder	0.00378	0.00635	CbGeAlD
Vandetanib—YES1—Innate Immune System—WASF1—conduct disorder	0.00122	0.00301	CbGpPWpGaD
Vandetanib—FMO3—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00121	0.003	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—MB21D1—conduct disorder	0.00121	0.00298	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—POLR3A—conduct disorder	0.0012	0.00298	CbGpPWpGaD
Vandetanib—SRC—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.0012	0.00298	CbGpPWpGaD
Vandetanib—SRC—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.0012	0.00298	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—WASF1—conduct disorder	0.00116	0.00288	CbGpPWpGaD
Vandetanib—YES1—Immune System—MB21D1—conduct disorder	0.00115	0.00284	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—POLR3A—conduct disorder	0.0011	0.00273	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CGA—conduct disorder	0.0011	0.00272	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—POLR3A—conduct disorder	0.00109	0.00269	CbGpPWpGaD
Vandetanib—LCK—Notch Signaling Pathway—EP300—conduct disorder	0.00109	0.00268	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—POLR3A—conduct disorder	0.00108	0.00267	CbGpPWpGaD
Vandetanib—SRC—Regulation of Androgen receptor activity—EP300—conduct disorder	0.00108	0.00266	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—POLR3A—conduct disorder	0.00107	0.00266	CbGpPWpGaD
Vandetanib—ABL1—p73 transcription factor network—EP300—conduct disorder	0.00107	0.00265	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.00107	0.00264	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—MB21D1—conduct disorder	0.00107	0.00264	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—WASF1—conduct disorder	0.00106	0.00263	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—POLR3A—conduct disorder	0.00106	0.00263	CbGpPWpGaD
Vandetanib—BLK—Immune System—POLR3A—conduct disorder	0.00105	0.00259	CbGpPWpGaD
Vandetanib—FGR—Immune System—POLR3A—conduct disorder	0.00104	0.00258	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00103	0.00256	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—WASF1—conduct disorder	0.00101	0.00251	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—CGA—conduct disorder	0.000993	0.00245	CbGpPWpGaD
Vandetanib—ABCG2—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000987	0.00244	CbGpPWpGaD
Vandetanib—SRC—Kit receptor signaling pathway—EP300—conduct disorder	0.000987	0.00244	CbGpPWpGaD
Vandetanib—SRC—Notch Signaling Pathway—EP300—conduct disorder	0.000961	0.00238	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—POLR3A—conduct disorder	0.00096	0.00237	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—WASF1—conduct disorder	0.000928	0.00229	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000922	0.00228	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—POLR3A—conduct disorder	0.000918	0.00227	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—WASF1—conduct disorder	0.000917	0.00227	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—WASF1—conduct disorder	0.000908	0.00225	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—WASF1—conduct disorder	0.000904	0.00224	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—WASF1—conduct disorder	0.000894	0.00221	CbGpPWpGaD
Vandetanib—VEGFA—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00089	0.0022	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—DRD4—conduct disorder	0.000889	0.0022	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000889	0.0022	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—POLR3A—conduct disorder	0.000885	0.00219	CbGpPWpGaD
Vandetanib—BLK—Immune System—WASF1—conduct disorder	0.000882	0.00218	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—WASF1—conduct disorder	0.000882	0.00218	CbGpPWpGaD
Vandetanib—FGR—Immune System—WASF1—conduct disorder	0.000879	0.00217	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—MB21D1—conduct disorder	0.000875	0.00216	CbGpPWpGaD
Vandetanib—ABL1—Cell Cycle—EP300—conduct disorder	0.000874	0.00216	CbGpPWpGaD
Vandetanib—VEGFA—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000867	0.00214	CbGpPWpGaD
Vandetanib—LYN—Immune System—MB21D1—conduct disorder	0.000856	0.00212	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MB21D1—conduct disorder	0.000852	0.00211	CbGpPWpGaD
Vandetanib—FYN—Immune System—MB21D1—conduct disorder	0.000843	0.00208	CbGpPWpGaD
Vandetanib—YES1—Immune System—POLR3A—conduct disorder	0.000843	0.00208	CbGpPWpGaD
Vandetanib—EGFR—Androgen receptor signaling pathway—EP300—conduct disorder	0.000833	0.00206	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—DRD4—conduct disorder	0.000813	0.00201	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000812	0.00201	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—WASF1—conduct disorder	0.000808	0.002	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—POLR3A—conduct disorder	0.000783	0.00194	CbGpPWpGaD
Vandetanib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000776	0.00192	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—WASF1—conduct disorder	0.000773	0.00191	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000758	0.00187	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—WASF1—conduct disorder	0.000745	0.00184	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—DRD4—conduct disorder	0.000744	0.00184	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CGA—conduct disorder	0.00074	0.00183	CbGpPWpGaD
Vandetanib—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000738	0.00182	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MB21D1—conduct disorder	0.000728	0.0018	CbGpPWpGaD
Vandetanib—SRC—Androgen receptor signaling pathway—EP300—conduct disorder	0.00071	0.00176	CbGpPWpGaD
Vandetanib—YES1—Immune System—WASF1—conduct disorder	0.00071	0.00175	CbGpPWpGaD
Vandetanib—LCK—Immune System—MB21D1—conduct disorder	0.000702	0.00174	CbGpPWpGaD
Vandetanib—EPHA5—Developmental Biology—EP300—conduct disorder	0.0007	0.00173	CbGpPWpGaD
Vandetanib—ABL2—Developmental Biology—EP300—conduct disorder	0.0007	0.00173	CbGpPWpGaD
Vandetanib—ABL1—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000694	0.00172	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CGA—conduct disorder	0.000677	0.00167	CbGpPWpGaD
Vandetanib—EPHA8—Developmental Biology—EP300—conduct disorder	0.000676	0.00167	CbGpPWpGaD
Vandetanib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000666	0.00165	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CGA—conduct disorder	0.000659	0.00163	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—WASF1—conduct disorder	0.000659	0.00163	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CGA—conduct disorder	0.000652	0.00161	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—POLR3A—conduct disorder	0.000642	0.00159	CbGpPWpGaD
Vandetanib—ABL1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000638	0.00158	CbGpPWpGaD
Vandetanib—LYN—Immune System—POLR3A—conduct disorder	0.000629	0.00155	CbGpPWpGaD
Vandetanib—TEK—Hemostasis—EP300—conduct disorder	0.000628	0.00155	CbGpPWpGaD
Vandetanib—EPHB6—Developmental Biology—EP300—conduct disorder	0.000628	0.00155	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—COMT—conduct disorder	0.000627	0.00155	CbGpPWpGaD
Vandetanib—ABL1—Immune System—POLR3A—conduct disorder	0.000626	0.00155	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—MAOA—conduct disorder	0.000622	0.00154	CbGpPWpGaD
Vandetanib—SRC—Immune System—MB21D1—conduct disorder	0.000621	0.00154	CbGpPWpGaD
Vandetanib—FYN—Immune System—POLR3A—conduct disorder	0.000619	0.00153	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—DRD4—conduct disorder	0.000616	0.00152	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CGA—conduct disorder	0.000615	0.00152	CbGpPWpGaD
Vandetanib—PLK4—Cell Cycle, Mitotic—EP300—conduct disorder	0.000607	0.0015	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—WASF1—conduct disorder	0.000593	0.00147	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CGA—conduct disorder	0.000593	0.00147	CbGpPWpGaD
Vandetanib—EPHA6—Developmental Biology—EP300—conduct disorder	0.000591	0.00146	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—HTR2A—conduct disorder	0.00058	0.00143	CbGpPWpGaD
Vandetanib—EGFR—Direct p53 effectors—EP300—conduct disorder	0.000579	0.00143	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CGA—conduct disorder	0.000572	0.00142	CbGpPWpGaD
Vandetanib—VEGFA—Cellular responses to stress—EP300—conduct disorder	0.000569	0.00141	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000562	0.00139	CbGpPWpGaD
Vandetanib—EGFR—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000545	0.00135	CbGpPWpGaD
Vandetanib—PLK4—Cell Cycle—EP300—conduct disorder	0.000542	0.00134	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—WASF1—conduct disorder	0.000542	0.00134	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—WASF1—conduct disorder	0.00054	0.00134	CbGpPWpGaD
Vandetanib—EGFR—Immune System—POLR3A—conduct disorder	0.000535	0.00132	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—HTR2A—conduct disorder	0.000531	0.00131	CbGpPWpGaD
Vandetanib—LYN—Immune System—WASF1—conduct disorder	0.000529	0.00131	CbGpPWpGaD
Vandetanib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000529	0.00131	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—WASF1—conduct disorder	0.000528	0.00131	CbGpPWpGaD
Vandetanib—ABL1—Immune System—WASF1—conduct disorder	0.000527	0.0013	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—WASF1—conduct disorder	0.000523	0.00129	CbGpPWpGaD
Vandetanib—FYN—Immune System—WASF1—conduct disorder	0.000521	0.00129	CbGpPWpGaD
Vandetanib—SRC—TGF-beta Signaling Pathway—EP300—conduct disorder	0.000518	0.00128	CbGpPWpGaD
Vandetanib—LCK—Immune System—POLR3A—conduct disorder	0.000515	0.00127	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000501	0.00124	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—HTR2A—conduct disorder	0.000485	0.0012	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—WASF1—conduct disorder	0.000475	0.00117	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CGA—conduct disorder	0.000461	0.00114	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—WASF1—conduct disorder	0.000459	0.00113	CbGpPWpGaD
Vandetanib—SRC—Immune System—POLR3A—conduct disorder	0.000456	0.00113	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000452	0.00112	CbGpPWpGaD
Vandetanib—EGFR—Immune System—WASF1—conduct disorder	0.00045	0.00111	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—COMT—conduct disorder	0.000448	0.00111	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—MAOA—conduct disorder	0.000445	0.0011	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CGA—conduct disorder	0.000436	0.00108	CbGpPWpGaD
Vandetanib—LCK—Immune System—WASF1—conduct disorder	0.000434	0.00107	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CGA—conduct disorder	0.000427	0.00106	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—EP300—conduct disorder	0.00042	0.00104	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CGA—conduct disorder	0.00042	0.00104	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD4—conduct disorder	0.000414	0.00102	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CGA—conduct disorder	0.000405	0.001	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—EP300—conduct disorder	0.000405	0.001	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HTR2A—conduct disorder	0.000402	0.000994	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000386	0.000953	CbGpPWpGaD
Vandetanib—SRC—Immune System—WASF1—conduct disorder	0.000384	0.000949	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—EP300—conduct disorder	0.000384	0.000949	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—EP300—conduct disorder	0.00038	0.00094	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD4—conduct disorder	0.000379	0.000937	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD4—conduct disorder	0.000369	0.000913	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD4—conduct disorder	0.000365	0.000903	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—EP300—conduct disorder	0.000365	0.000901	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CGA—conduct disorder	0.000363	0.000898	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000356	0.000881	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000354	0.000875	CbGpPWpGaD
Vandetanib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000352	0.000869	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CGA—conduct disorder	0.00035	0.000865	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—WASF1—conduct disorder	0.000349	0.000864	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—EP300—conduct disorder	0.000345	0.000853	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD4—conduct disorder	0.000344	0.000851	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—WASF1—conduct disorder	0.000342	0.000846	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—EP300—conduct disorder	0.000338	0.000837	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—WASF1—conduct disorder	0.000337	0.000833	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—EP300—conduct disorder	0.000335	0.000829	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—EP300—conduct disorder	0.000333	0.000824	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD4—conduct disorder	0.000332	0.00082	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—EP300—conduct disorder	0.000327	0.000808	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD4—conduct disorder	0.000321	0.000793	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CGA—conduct disorder	0.00031	0.000766	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—EP300—conduct disorder	0.000307	0.00076	CbGpPWpGaD
Vandetanib—MKNK1—Disease—EP300—conduct disorder	0.000304	0.000752	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—EP300—conduct disorder	0.000294	0.000728	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—WASF1—conduct disorder	0.000291	0.000719	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—EP300—conduct disorder	0.000281	0.000695	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—WASF1—conduct disorder	0.00028	0.000693	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HTR2A—conduct disorder	0.00027	0.000668	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—EP300—conduct disorder	0.000269	0.000664	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EP300—conduct disorder	0.000257	0.000636	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CGA—conduct disorder	0.00025	0.000618	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EP300—conduct disorder	0.000248	0.000614	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—WASF1—conduct disorder	0.000248	0.000614	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EP300—conduct disorder	0.000247	0.000611	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HTR2A—conduct disorder	0.000247	0.000611	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EP300—conduct disorder	0.000245	0.000605	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EP300—conduct disorder	0.000245	0.000605	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD4—conduct disorder	0.000244	0.000604	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—EP300—conduct disorder	0.000244	0.000603	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—EP300—conduct disorder	0.000243	0.0006	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HTR2A—conduct disorder	0.000241	0.000596	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—EP300—conduct disorder	0.00024	0.000593	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD4—conduct disorder	0.000239	0.000591	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HTR2A—conduct disorder	0.000238	0.000589	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD4—conduct disorder	0.000235	0.000582	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HTR2A—conduct disorder	0.000225	0.000555	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EP300—conduct disorder	0.000224	0.000554	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EP300—conduct disorder	0.000221	0.000548	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EP300—conduct disorder	0.000219	0.000542	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EP300—conduct disorder	0.000218	0.00054	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HTR2A—conduct disorder	0.000217	0.000535	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EP300—conduct disorder	0.000216	0.000534	CbGpPWpGaD
Vandetanib—BLK—Immune System—EP300—conduct disorder	0.000213	0.000527	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EP300—conduct disorder	0.000213	0.000527	CbGpPWpGaD
Vandetanib—FGR—Immune System—EP300—conduct disorder	0.000212	0.000525	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—EP300—conduct disorder	0.000211	0.000522	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HTR2A—conduct disorder	0.000209	0.000517	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—COMT—conduct disorder	0.000208	0.000514	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MAOA—conduct disorder	0.000206	0.00051	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD4—conduct disorder	0.000203	0.000503	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.0002	0.000495	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—EP300—conduct disorder	0.0002	0.000494	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD4—conduct disorder	0.000196	0.000484	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EP300—conduct disorder	0.000195	0.000483	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—EP300—conduct disorder	0.000192	0.000475	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—EP300—conduct disorder	0.000187	0.000461	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—COMT—conduct disorder	0.000183	0.000452	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MAOA—conduct disorder	0.000182	0.000449	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EP300—conduct disorder	0.00018	0.000446	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EP300—conduct disorder	0.00018	0.000446	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EP300—conduct disorder	0.00018	0.000445	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—EP300—conduct disorder	0.000177	0.000437	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD4—conduct disorder	0.000173	0.000429	CbGpPWpGaD
Vandetanib—YES1—Immune System—EP300—conduct disorder	0.000171	0.000424	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HTR2A—conduct disorder	0.000159	0.000394	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EP300—conduct disorder	0.000159	0.000394	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HTR2A—conduct disorder	0.000156	0.000386	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HTR2A—conduct disorder	0.000154	0.00038	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EP300—conduct disorder	0.000143	0.000354	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CGA—conduct disorder	0.000135	0.000334	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR2A—conduct disorder	0.000133	0.000328	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EP300—conduct disorder	0.000131	0.000324	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EP300—conduct disorder	0.000131	0.000323	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR2A—conduct disorder	0.000128	0.000316	CbGpPWpGaD
Vandetanib—LYN—Immune System—EP300—conduct disorder	0.000128	0.000316	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EP300—conduct disorder	0.000128	0.000316	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EP300—conduct disorder	0.000127	0.000314	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EP300—conduct disorder	0.000126	0.000312	CbGpPWpGaD
Vandetanib—FYN—Immune System—EP300—conduct disorder	0.000126	0.000311	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EP300—conduct disorder	0.000121	0.000298	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—EP300—conduct disorder	0.000119	0.000295	CbGpPWpGaD
Vandetanib—FYN—Disease—EP300—conduct disorder	0.000116	0.000287	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EP300—conduct disorder	0.000115	0.000284	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—conduct disorder	0.000113	0.00028	CbGpPWpGaD
Vandetanib—ALB—Metabolism—COMT—conduct disorder	0.000113	0.000279	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MAOA—conduct disorder	0.000112	0.000277	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EP300—conduct disorder	0.000111	0.000274	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000109	0.000269	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EP300—conduct disorder	0.000109	0.000269	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EP300—conduct disorder	0.000106	0.000263	CbGpPWpGaD
Vandetanib—LCK—Immune System—EP300—conduct disorder	0.000105	0.000259	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—conduct disorder	0.0001	0.000248	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—conduct disorder	9.67e-05	0.000239	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—conduct disorder	9.27e-05	0.000229	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—conduct disorder	8.92e-05	0.00022	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—conduct disorder	8.56e-05	0.000212	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—conduct disorder	8.44e-05	0.000209	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—conduct disorder	8.26e-05	0.000204	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—conduct disorder	8.13e-05	0.000201	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—conduct disorder	7.85e-05	0.000194	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—conduct disorder	7.03e-05	0.000174	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—conduct disorder	6.77e-05	0.000167	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—conduct disorder	6.09e-05	0.000151	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MAOA—conduct disorder	6.05e-05	0.00015	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—conduct disorder	6e-05	0.000148	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—conduct disorder	4.84e-05	0.00012	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—conduct disorder	2.61e-05	6.46e-05	CbGpPWpGaD
